ANCA-associated vasculitis (AAV) may lead to long-term organ damage and has a significant mortality risk for patients. While glucocorticoids are effective, they are associated with adverse events and impaired quality of life. Join our experts as they tackle these unmet needs in the context of the guidelines and current treatments and then dive deeper with an exploration of the potential role of complement receptor inhibition, which may be the answer to improving vasculitis.
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
David Jayne, MD
Professor of Clinical Autoimmunity
Department of Medicine
University of Cambridge
Cambridge, United Kingdom
Research: GSK, Roche
Ownership Interest: Aurinia
Consulting Fees: Amgen, AstraZeneca, Bristol Myers Squibb, GSK, Novartis, Roche, Takeda, Vifor Pharma
Annette Bruchfeld, MD, PhD
Professor of Nephrology
Consulting Fees: AstraZeneca, Bayer, ChemoCentryx, Vifor Pharma
Speaker´s honoraria: AbbVie, AstraZeneca, Fresenius, MSD, Vifor Pharma
- Megan Clem has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
- Kate Nagele has nothing to disclose.
- Katie Sheridan, PhD, has nothing to disclose.
After participating in this educational activity, participants should be better able to:
- Interpret the clinical relevance of clinical trial data for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) therapies
- Select and initiate glucocorticoid (GC)-sparing induction regimens
- Develop treatment plans for patients with AAV using C5a receptor inhibitors and GC tapering
This activity is designed to meet the educational needs of nephrologists and rheumatologists.
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at firstname.lastname@example.org.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
This activity is supported by an independent educational grant from CSL Vifor.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Jürgen Floege, MD
Jonathan Barratt, PhD
Renuka Jain, MD
Hemal Gada, MD
Pam R. Taub, MD, FACC, FASPC
Steven Yakubov, MD, MSCAI, FACC